Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1003 for reduction of scarring in incisional wounds
2004-001455-11Phase 2Completed
- Sponsor
- Renovo
- Start
- Feb 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interleukin 10 in scar (3 arms), sponsored by Renovo. Primary endpoint: External scar assessment VAS score at 12 months. Started Feb 2005; status: completed.
02
Drugs
interleukin 10
03
Conditions
scar
Beyond the preview
Go deeper on 2004-001455-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001455-11.